4093-34-9

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 4-acetamido-5-bromo-2-methoxybenzoate is used as an impurity in the production of bromopride, an antimetic drug, for its role in managing nausea and vomiting in patients.

Flammability and Explosibility

Notclassified

InChI:InChI=1/C11H12BrNO4/c1-6(14)13-9-5-10(16-2)7(4-8(9)12)11(15)17-3/h4-5H,1-3H3,(H,13,14)

Upstream product

• 4093-29-2 methyl 4-(acetylamino)-o-anisate 
• 65-49-6 4-Aminosalicylic acid 
• 4136-97-4 methyl 4-aminosalicylate 
• 27492-84-8 Methyl 4-amino-2-methoxybenzoate 
• 39106-79-1 methyl 2-methoxy-4-nitrobenzoate 
• 4093-28-1 methyl 4-acetamido-2-hydroxybenzoate 

Downstream Products

• 35290-97-2 4-amino 5-bromo 2-methoxy benzoic acid 

Relevant academic research and scientific papers

Preparation method for pharmacopoeia impurity of amisulpride

The invention reports a preparation method for a pharmacopoeia impurity of amisulpride, and particularly relates to a preparation method for the pharmacopoeia impurity D of amisulpride. The method is simple and easy to operate, mild in condition, high in yield, low in energy consumption and pollution and suitable for laboratory-level standard substance preparation.

FUNGICIDAL ARYL AMIDINES

This disclosure relates to aryl amidines of Formula I and their use as fungicides. One embodiment of the present disclosure is a use of a compound of Formula I, for protection of a plant against attack by a phytopathogenic organism or the treatment of a plant infested by a phytopathogenic organism, comprising the application of a compound of Formula I, or a composition comprising the compound to soil, a plant, a part of a plant, foliage, and/or roots.

QUINAZOLINE-BASED KINASE INHIBITORS

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

A halogen halide for preparing 2-methoxy-4-amino-5-b sulfuryl method of methyl benzoate

The invention relates to a method for preparing 2-methoxy-4-amino-5-ethysulfonyl benzoic acid methyl ester by halogen halogenation. According to the invention, 2-methoxy-4-acetyl methyl anthranilate is subjected to halogen halogenation (chlorination, bromination or iodization) and then is condensed with sodium ethanesulfinate to obtain a target product. The method has the advantages that the process route is simple, the product yield is high, the total yield reaches 80 percent, the product quality is high, the purity reaches 99.5 percent, and the appearance is white.

ANTIVIRAL COMPOUNDS

Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

ARYL AMIDE KINASE INHIBITORS

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

Synthesis and biological evaluation of berberine derivatives as IBS modulator

Irritable bowel syndrome is the most common functional gastrointestinal disorder characterized by chronic abdominal pain or discomfort in association with a change in bowel habit. 5-HT receptor modulators have been developed as IBS therapeutic agents and proved to be effective in the treatment of the disease. In this letter, 12 berberine derivatives were designed and synthesized as 5-HT receptor modulators. Preliminary biological tests suggested that the new compounds exhibited promising activity for IBS therapy.

Highly selective C-H functionalization/halogenation of acetanilide

Highly regioselective C-H functionalization/halogenation of acetanilides to produce ortho-haloacetanilides was catalyzed by Pd(OAc)2 and Cu(OAc)2 with CuX2 as the halogen source. Copyright

Bromopride: Metabolism and urinary elimination in dogs

The elimination of bromopride and its metabolites was studied in dogs. The drug was given by mouth in a single dose of 15 mg/kg or 45 mg/kg and assessed by thin-layer or gas chromatography. Bromopride and its metabolites are excreted mainly within the first 8 h after ingestion. Nine metabolites, above all the N-monodeethyl derivative, were encountered, while 10% of the drug was eliminated as such.